Antares Pharma (ATRS) Misses Q1 EPS by 2c

Antares Pharma (NASDAQ: ATRS) reported Q1 EPS of ($0.07), $0.02 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $5.2 million versus the consensus estimate of $6.17 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Sunstone Hotel Investors to sell Hyatt Regency San Francisco for $279M
• Deutsche Bank Starts DexCom (DXCM) at Buy